Westinghouse Signs Contract for Engineering of AP1000 ® Reactors in Bulgaria
4.11.2024 22:12:00 EET | Business Wire | Press release
Westinghouse Electric Company, Hyundai Engineering & Construction Co. and Bulgaria’s Kozloduy NPP - New Build EAD today signed the Engineering Services Contract for two AP1000® reactors to be built at the Kozloduy site. Bulgarian Prime Minister Dimitar Glavchev, Bulgarian Minister of Energy Vladimir Malinov, U.S. Ambassador to Bulgaria Kenneth Merten, Executive Director of Kozloduy NPP - New Build Petyo Ivanov, Senior Vice President of Westinghouse Energy Systems Elias Gedeon, and Hyundai Engineering & Construction President and CEO Yoon Young-Joon attended the signing ceremony in Sofia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104293861/en/
Following the signing ceremony. From left: Yoon Young-Joon, President and CEO, Hyundai Engineering & Construction; Ji I Cho, Deputy Head of Mission and Charge d'Affaires a.i., Embassy of the Republic of Korea; Vladimir Malinov, Minister of Energy, Bulgaria; Dimitar Glavchev, Prime Minister of Bulgaria; Elias Gedeon, Senior Vice President of Westinghouse Energy Systems; Kenneth Merten, U.S. Ambassador to Bulgaria; and Petyo Ivanov, Executive Director, Kozloduy NPP - New Build. (Photo: Business Wire)
The contract scope includes site planning for two Westinghouse AP1000® units, the most advanced Generation III+ nuclear reactor available today. In addition, the contract provides support for Kozloduy NPP - New Build EAD to begin licensing and permitting, while providing critical project planning and operations & maintenance development. The work outlined in the 12-month contract will begin immediately.
“Bulgaria has over 50 years of experience in the construction of nuclear facilities. And today's event will build on this experience and contribute to the independence, diversification and stability of nuclear energy in the country and throughout Europe. We are pleased to partner on the new build project with Westinghouse Electric Company and Hyundai Engineering & Construction, which are undisputed leaders in this field. I am convinced of the great success of the project, and the Bulgarian state will give its maximum for its successful implementation,” said Dimitar Glavchev, Bulgarian Prime Minister.
“The main priority of our cabinet is the development of nuclear energy. Our consistent efforts in this direction have led to today's event. We are thankful to Westinghouse Electric Company and Hyundai Engineering & Construction for responding to our request and forming a consortium. I believe that in less than 10 years we will have a working project that will be a guarantee for the Bulgarian population and country, that we will have clean energy at an affordable price,” said Vladimir Malinov, Bulgarian Minister of Energy.
“The United States fully supports Bulgaria’s efforts to ensure its energy security through the diversification of its energy sector. The construction of these two new reactors will both enhance Bulgaria’s energy security and position the country as a key energy hub for the region,” said Kenneth Merten, U.S. Ambassador to Bulgaria. “This project, using advanced American technology with unparalleled safety standards over years of safe operation, is poised to provide sustainable and secure energy for Bulgaria’s future.”
“We are pleased to extend our long-term relationship with Bulgaria, and to work closely in building two advanced AP1000 units that will bolster Bulgaria’s energy security,” said Dan Lipman, President of Westinghouse Energy Systems. “This project will not only deliver clean, safe and stable power to Bulgaria, it will also create high-quality jobs and real economic benefits for years to come and foster Bulgaria’s energy independence.”
Bulgaria’s first AP1000 nuclear reactor is anticipated to achieve commercial operation in 2035. Westinghouse has already signed Memoranda of Understanding with 22 Bulgarian suppliers to support the project. The two-unit Kozloduy project will also provide Bulgarian firms opportunities to support the more than 30 AP1000 units in the pipeline globally.
The AP1000 reactor is the only operating Generation III+ reactor with fully passive safety systems, modular construction design and the smallest footprint per MWe on the market. In China, there are four AP1000 reactors currently setting operational performance and availability records with eight additional reactors under construction and four more under contract. In addition, there are two operating AP1000 units at the Vogtle site in Georgia. The AP1000 technology has been selected for nuclear energy programs in Poland, Ukraine and Bulgaria, and is also under consideration at multiple other sites in Central and Eastern Europe, the United Kingdom, India and North America. There will be 18 units based on AP1000 technology in operation globally by the end of the decade.
Westinghouse Electric Company is shaping the future of carbon-free energy by providing safe, innovative nuclear and other clean power technologies and services globally. Westinghouse supplied the world’s first commercial pressurized water reactor in 1957 and the company’s technology is the basis for nearly one-half of the world's operating nuclear plants. Over 135 years of innovation makes Westinghouse the preferred partner for advanced technologies covering the complete nuclear energy life cycle. For more information, visit www.westinghousenuclear.com and follow us on Facebook, LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104293861/en/
Contacts
media@westinghouse.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom